Navigation Links
Drug Improves Survival in Mice With Brain Tumors
Date:4/2/2009

Cediranib reduces tissue swelling better than steroids, team says

THURSDAY, April 2 (HealthDay News) -- Anti-angiogenesis drugs reduce edema (swelling of brain tissue) caused by deadly brain tumors called glioblastomas, a new study suggests.

Anti-angiogenesis drugs prevent the formation of new blood vessels that tumors need to grow, the researchers pointed out.

In this study, a Massachusetts General Hospital team found that the experimental anti-angiogenesis drug cediranib reduced edema and improved survival in mice with glioblastomas. The drug inhibits an angiogenesis factor called VEGF, which is abundant in glioblastomas.

"Our findings suggest that anti-angiogenesis therapy can increase patient survival even in the face of persistent tumor growth," study co-senior author Rakesh K. Jain, director of the Steele Laboratory in MGH's radiation oncology department, said in a hospital news release. "In glioblastoma clinical trials, it is important to separate survival analysis from that of tumor response to therapy, since many factors combine to cause patient deaths."

Previous research showed that cediranib temporarily normalized abnormal, leaky blood vessels that had recurred after surgery, radiation or chemotherapy for glioblastoma, reducing edema and the size of tumors. But exactly how the drug did this was unclear. This study clarified that cediranib's beneficial effects resulted from reduction of edema, the study authors said.

"This is the first paper to show that vascular normalization alone, without chemotherapy, can be effective against some tumors by controlling edema, and that this anti-edema effect is better than that of currently used steroids," Jain said.

"Unfortunately, these anti-VEGF agents did not slow the tumor growth rate in these [mouse] models; and since recurrent glioblastomas are highly resistant to currently used chemotherapy drugs, even if vascular normalization increased drug delivery, there may be little or no additional increase in patient survival. We urgently need to find better anti-tumor and anti-angiogenic agents."

The study, which was published online and is expected to be in a future print issue of the Journal of Clinical Oncology, received funding from AstraZeneca Pharmaceuticals, which manufactures cediranib under the brand name Recentin.

More information

The American Brain Tumor Association has more about brain tumors.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, March 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Exercise and yoga improves quality of life in women with early-stage breast cancer
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
5. Kerry Extends, Improves Small Business Innovation Program
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. Grape Consumption Improves Antioxidant Capacity in Humans
8. JCSM: CPAP therapy improves symptoms of depression in OSA patients
9. Early intervention dramatically improves outcomes for new dialysis patients
10. New technique improves purity of medicines
11. Novel medication improves ovarian cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Improves Survival in Mice With Brain Tumors
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the sound ... forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her three ... began journaling conversations and situations throughout my divorce,” James said. “After the death of ...
(Date:4/24/2017)... ... 24, 2017 , ... The world-class designers of Happy Gadget ... novel lifesaving device for the everyday use of parents worldwide. It is a ... read a child’s vital signs, and detect unusual symptoms or physical patterns. This ...
(Date:4/24/2017)... ... 24, 2017 , ... symplrTM, a leading provider of software ... Kyle Allain has joined the company as Vice President and General Manager of ... payor and managed care solutions. , A seasoned executive with more than ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP ... elevated anxiety levels in people with addiction who are served by MAP’s patient ... biosensing wearable device that monitors heart and breath rates to identify anxiety levels ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for ... The good news for single women is that she put all the words in ... April 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... 2017 Research and Markets has announced the ... to their offering. ... arthroscopy devices market to grow at a CAGR of 6.35% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Medicine Technology: